|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2000-2-17
|
|
pubmed:abstractText |
To assess the feasibility, pharmacokinetic interaction, and possible sequence-dependent effects of the irinotecan/cisplatin combination given every 3 weeks, and to assess the influence of additional granulocyte colony-stimulating factor (G-CSF) on the hematologic toxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
187-94
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10623709-Adult,
pubmed-meshheading:10623709-Aged,
pubmed-meshheading:10623709-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10623709-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10623709-Area Under Curve,
pubmed-meshheading:10623709-Camptothecin,
pubmed-meshheading:10623709-Cisplatin,
pubmed-meshheading:10623709-Dose-Response Relationship, Drug,
pubmed-meshheading:10623709-Female,
pubmed-meshheading:10623709-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:10623709-Humans,
pubmed-meshheading:10623709-Infusions, Intravenous,
pubmed-meshheading:10623709-Least-Squares Analysis,
pubmed-meshheading:10623709-Male,
pubmed-meshheading:10623709-Maximum Tolerated Dose,
pubmed-meshheading:10623709-Middle Aged,
pubmed-meshheading:10623709-Neutropenia,
pubmed-meshheading:10623709-Topoisomerase I Inhibitors
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
|
|
pubmed:affiliation |
Department of Medical Oncology, Rotterdam Cancer Institute, University Hospital Rotterdam, Rotterdam, the Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
